 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Pharmacokinetic data | |
| Protein binding | ~89% |
| Eliminationhalf-life | 2.5–5.5 hours |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL |
|
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.006.546 |
| Chemical and physical data | |
| Formula | C9H10N2O3S2 |
| Molar mass | 258.31 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Ethoxzolamide (alternatively known asethoxyzolamide) is asulfonamidemedication that functions as acarbonic anhydrase inhibitor.[1] It is used in the treatment ofglaucoma andduodenalulcers, and as adiuretic. It may also be used in the treatment of some forms ofepilepsy.
Ethoxzolamide, asulfonamide, inhibitscarbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate. It also decreases carbonic anhydrase in the CNS, increasing theseizure threshold. This reduction in carbonic anhydrase also reduces theintraocular pressure in the eye by decreasing aqueous humor.
Ethoxzolamide binds and inhibits carbonic anhydrase I. Carbonic anhydrase plays an essential role in facilitating the transport ofcarbon dioxide and protons in theintracellular space, across biological membranes and in the layers of the extracellular space. The inhibition of thisenzyme effects the balance of applicable membrane equilibrium systems.
